The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications
Molecular Cancer,
Год журнала:
2025,
Номер
24(1)
Опубликована: Янв. 15, 2025
The
polymorphic
microbiome
is
considered
a
new
hallmark
of
cancer.
Advances
in
High-Throughput
Sequencing
have
fostered
rapid
developments
research.
interaction
between
cancer
cells,
immune
and
microbiota
defined
as
the
immuno-oncology
(IOM)
axis.
Fungal
microbes
(the
mycobiome),
although
representing
only
∼
0.1-1%
microbiome,
are
critical
immunologically
active
component
tumor
microbiome.
Accumulating
evidence
suggests
possible
involvement
commensal
pathogenic
fungi
initiation,
progression,
treatment
responsiveness.
tumor-associated
mycobiome
mainly
consists
gut
mycobiome,
oral
intratumoral
mycobiome.
However,
role
remains
poorly
understood,
diversity
complexity
analytical
methods
make
it
challenging
to
access
this
field.
This
review
aims
elucidate
causal
complicit
roles
development
progression
while
highlighting
issues
that
need
be
addressed
executing
such
We
systematically
summarize
advantages
limitations
current
fungal
detection
analysis
methods.
enumerate
integrate
these
recent
findings
into
our
understanding
accompanied
by
prospect
novel
exhilarating
clinical
implications.
Язык: Английский
Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(2), С. 856 - 856
Опубликована: Янв. 20, 2025
Recent
studies
have
highlighted
that
the
microbiome
is
essential
factor
can
modulate
clinical
activity
of
immunotherapy.
However,
role
varies
significantly
across
different
immunotherapies,
suggesting
it
critical
to
understand
precise
function
in
each
type
While
many
previous
primarily
focus
on
summarizing
immune
checkpoint
inhibitors,
we
seek
explore
a
novel
aspect
other
immunotherapies
such
as
mesenchymal
stem
cell
therapy,
chimeric
antigen
receptor
T
and
antibodies-based
therapy
(e.g.,
adalimumab,
infliximab,
bevacizumab,
denosumab,
etc.)
which
are
rarely
summarized
reviews.
Moreover,
highlight
innovative
strategies
for
utilizing
microbial
metabolites
enhance
response
Collectively,
believe
our
manuscript
will
provide
insights
approaches
researchers,
could
drive
development
next
generation
personalized
therapeutic
interventions
using
microbiomes.
Язык: Английский
Optimizing Cancer Treatment Through Gut Microbiome Modulation
Kyuri Kim,
Mingyu Lee,
Yoojin Shin
и другие.
Cancers,
Год журнала:
2025,
Номер
17(7), С. 1252 - 1252
Опубликована: Апрель 7, 2025
The
gut
microbiome
plays
a
pivotal
role
in
modulating
cancer
therapies,
including
immunotherapy
and
chemotherapy.
Emerging
evidence
demonstrates
its
influence
on
treatment
efficacy,
immune
response,
resistance
mechanisms.
Specific
microbial
taxa
enhance
checkpoint
inhibitor
while
dysbiosis
can
contribute
to
adverse
outcomes.
Chemotherapy
effectiveness
is
also
influenced
by
composition,
with
engineered
probiotics
prebiotics
offering
promising
strategies
drug
delivery
reduce
toxicity.
Moreover,
metabolites,
such
as
short-chain
fatty
acids,
systems
have
shown
potential
improve
therapeutic
responses.
These
findings
underscore
the
importance
of
personalized
microbiome-based
approaches
optimizing
treatments.
Язык: Английский
Multi-cohort analysis reveals colorectal cancer tumor location-associated fecal microbiota and their clinical impact
Cell Host & Microbe,
Год журнала:
2025,
Номер
33(4), С. 589 - 601.e3
Опубликована: Апрель 1, 2025
Microbial
alterations
in
different
tumor
locations
of
colorectal
cancer
(CRC)
remain
unclear.
Here,
1,375
fecal
metagenomes
from
six
in-house
and
published
datasets
were
analyzed,
including
128
right-sided
CRC
(rCRC),
168
left-sided
(lCRC),
250
rectal
(RC),
829
controls.
Firmicutes
progressively
increase
rCRC,
lCRC,
to
RC,
contrast
the
gradual
decrease
Bacteroidetes.
Tumor
location-associated
microbes
are
identified,
Veillonella
parvula
for
Streptococcus
angionosus
Peptostreptococcus
anaerobius
while
Fusobacterium
nucleatum
is
enriched
all
locations.
bacteria
correlate
with
patient
survival.
Clinically,
we
establish
a
microbial
biomarker
panel
each
location
that
accurately
diagnoses
rCRC
(area
under
receiver
operating
characteristic
curve
[AUC]
=
91.59%),
lCRC
(AUC
91.69%),
or
RC
90.53%)
location-specific
biomarkers
also
have
higher
diagnostic
accuracy
91.38%)
than
location-non-specific
82.92%).
Overall,
characterize
associated
locations,
highlighting
should
be
considered
non-invasive
diagnosis.
Язык: Английский
Immune checkpoint inhibitors: From friend to foe
Toxicology Reports,
Год журнала:
2025,
Номер
unknown, С. 102033 - 102033
Опубликована: Апрель 1, 2025
Язык: Английский
Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors
Cancers,
Год журнала:
2024,
Номер
16(24), С. 4271 - 4271
Опубликована: Дек. 23, 2024
Immunotherapy
with
immune
checkpoint
inhibitors
represents
a
revolutionary
approach
to
the
treatment
of
solid
tumors,
including
malignant
melanoma,
lung
cancer,
and
gastrointestinal
malignancies.
Anti-CTLA-4
anti-PD-1/PDL-1
therapies
provide
prolonged
survival
for
cancer
patients,
but
their
efficacy
safety
are
highly
variable.
This
review
focuses
on
crucial
role
gut
microbiome
in
modulating
toxicity
blockade.
Studies
suggest
that
composition
may
influence
response
immunotherapy,
specific
bacterial
strains
able
promote
an
anti-tumor
response.
On
other
hand,
dysbiosis
increase
risk
adverse
effects,
such
as
immune-mediated
colitis.
Interventions
aimed
at
microbiome,
use
probiotics,
prebiotics,
fecal
microbial
transplantation,
or
dietary
modifications,
represent
promising
strategies
reduce
toxicity.
The
combination
immunotherapy
microbiome-based
strategy
opens
up
new
possibilities
personalized
treatment.
In
addition,
factors
physical
activity
nutritional
supplementation
indirectly
ecosystem
consequently
improve
outcomes
refractory
leading
enhanced
patient
responses
survival.
Язык: Английский